Literature DB >> 19300954

Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Eilhard Mix1, Hans Meyer-Rienecker, Uwe K Zettl.   

Abstract

Various types of experimental autoimmune encephalomyelitis (EAE) reflect some of the pathogenetic, clinical, and therapeutic features of the different forms of multiple sclerosis (MS), thereby, providing some, albeit limited, insight into the molecular and cellular basis of the human disease. Specific questions of MS therapy including the search for new therapeutic targets and strategies and their validation require investigations in different available EAE models. A survey is given of experimental therapeutic approaches that are currently under study with the most promising examples of monoclonal antibodies, gene therapy, stem cell transplantation and orally applied small molecular weight disease-modifying drugs. Reasons for therapy failure and adverse side-effects of some experimental trials are discussed. Precaution is advised, if results of new experimental approaches are translated into clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19300954     DOI: 10.1007/s00415-008-6003-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  105 in total

1.  Development of cladribine treatment in multiple sclerosis.

Authors:  J C Sipe; J S Romine; J A Koziol; R McMillan; J Zyroff; E Beutler
Journal:  Mult Scler       Date:  1996-07       Impact factor: 6.312

2.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

3.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

4.  Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.

Authors:  Orhan Aktas; Timour Prozorovski; Alina Smorodchenko; Nicolai E Savaskan; Roland Lauster; Peter-Michael Kloetzel; Carmen Infante-Duarte; Stefan Brocke; Frauke Zipp
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

5.  IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions.

Authors:  Signe Humle Jorgensen; Nicolas Storm; Poul Erik Hyldgaard Jensen; Henning Laursen; Per Soelberg Sorensen
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

6.  Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.

Authors:  Laura Garay; Maria Claudia Gonzalez Deniselle; Lobke Gierman; Maria Meyer; Analia Lima; Paulina Roig; Alejandro F De Nicola
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

Review 7.  Central nervous system-directed effects of FTY720 (fingolimod).

Authors:  Veronique E Miron; Anna Schubart; Jack P Antel
Journal:  J Neurol Sci       Date:  2008-08-03       Impact factor: 3.181

8.  Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis.

Authors:  M B Sättler; D Merkler; K Maier; C Stadelmann; H Ehrenreich; M Bähr; R Diem
Journal:  Cell Death Differ       Date:  2004-12       Impact factor: 15.828

9.  Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis.

Authors:  Tapas K Makar; David Trisler; Christopher T Bever; James E Goolsby; Karna T Sura; Shailesh Balasubramanian; Shireen Sultana; Niraj Patel; David Ford; Ishwar S Singh; Aditi Gupta; Reuben M Valenzuela; Suhayl Dhib-Jalbut
Journal:  J Neuroimmunol       Date:  2008-05-08       Impact factor: 3.478

Review 10.  Emerging oral therapies for multiple sclerosis.

Authors:  B A Cohen; P Rieckmann
Journal:  Int J Clin Pract       Date:  2007-09-03       Impact factor: 2.503

View more
  29 in total

Review 1.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 2.  Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models.

Authors:  Robert H Miller; Sharyl L Fyffe-Maricich
Journal:  Dis Model Mech       Date:  2010-07-20       Impact factor: 5.758

Review 3.  Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease.

Authors:  Florian Rieder; Sean Kessler; Miquel Sans; Claudio Fiocchi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-09       Impact factor: 4.052

4.  Induction of a regulatory B cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora.

Authors:  Javier Ochoa-Repáraz; Daniel W Mielcarz; Sakhina Haque-Begum; Lloyd H Kasper
Journal:  Gut Microbes       Date:  2010-02-15

5.  Evaluation of a transgenic mouse model of multiple sclerosis with noninvasive methods.

Authors:  Mabel Enriquez-Algeciras; Di Ding; Tsung-Han Chou; Jianhua Wang; Kyle R Padgett; Vittorio Porciatti; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-14       Impact factor: 4.799

Review 6.  Brain dendritic cells: biology and pathology.

Authors:  Paul M D'Agostino; Andres Gottfried-Blackmore; Niroshana Anandasabapathy; Karen Bulloch
Journal:  Acta Neuropathol       Date:  2012-07-24       Impact factor: 17.088

Review 7.  Spontaneous ocular and neurologic deficits in transgenic mouse models of multiple sclerosis and noninvasive investigative modalities: a review.

Authors:  Archana A Gupta; Di Ding; Richard K Lee; Robert B Levy; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-13       Impact factor: 4.799

8.  Glutamate release machinery is altered in the frontal cortex of rats with experimental autoimmune encephalomyelitis.

Authors:  Natalí L Chanaday; A Alejandro Vilcaes; Ana L de Paul; Alicia I Torres; Alicia L Degano; German A Roth
Journal:  Mol Neurobiol       Date:  2014-07-19       Impact factor: 5.590

9.  A regenerative approach to the treatment of multiple sclerosis.

Authors:  Brian R Lawson; Peter G Schultz; Luke L Lairson; Vishal A Deshmukh; Virginie Tardif; Costas A Lyssiotis; Chelsea C Green; Bilal Kerman; Hyung Joon Kim; Krishnan Padmanabhan; Jonathan G Swoboda; Insha Ahmad; Toru Kondo; Fred H Gage; Argyrios N Theofilopoulos
Journal:  Nature       Date:  2013-10-09       Impact factor: 49.962

Review 10.  Preclinical assessment of stem cell therapies for neurological diseases.

Authors:  Valerie L Joers; Marina E Emborg
Journal:  ILAR J       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.